The benefit of the addition of perioperative pembrolizumab to standard care with surgery and adjuvant therapy for patients with locally advanced head and neck squamous-cell carcinoma (HNSCC) is unc ...

The ALNEO trial's final analysis shows neoadjuvant alectinib is effective and well tolerated in resectable stage III ALK-positive NSCLC, achieving 42% MPR and 67% ORR, suggesting a feasible ...

Perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) is a standard therapy for resectable gastric and gastroesophageal junction adenocarcinomas, but recurrence rates remain hig ...

Total neoadjuvant therapy with induction immunochemotherapy and chemoradiotherapy followed by surgery for locally advanced esophageal squamous cell carcinoma (TNT-ESCC).. If you have the appropriate ...

The optimal time from surgery to initiation of adjuvant therapy remains undefined. Preclinical and clinical data suggest that starting earlier rather than later is beneficial.

The addition of olaparib to neoadjuvant chemotherapy improved overall survival in BRCA -mutated breast cancer, despite no improvement in pathologic response. Adding the PARP inhibitor led to a 3 ...

Neoadjuvant mitomycin C showed a favorable safety profile with mild to moderate side effects, including hematuria, dysuria, and itchy scalp. The trial did not show significant improvement in 12-month ...

PD-1 immunotherapy can eliminate the need for surgery in patients with early-stage, DNA mismatch repair-deficient solid cancers, according to results presented by Andrea Cercek, MD, at the AACR ...

Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Omission of Radiotherapy or Not? The following represents disclosure information provided by authors of this manuscript. All relationships are ...

Residual cancer after neoadjuvant therapy predicts recurrence years later in men undergoing surgery for high-risk prostate cancer.

Neoadjuvant chemotherapy is chemotherapy that's given before your primary treatment. Learn when it's used, course of treatment, benefits, and effectiveness.

Neoadjuvant Chemoradiation Plus Immunotherapy Boosts Responses in Esophageal Cancer — Phase III trial suggests regimen "has the potential to become the new standard of care" ...